Regulatory News

CE certification for HCV (Hepatitis C) screening kit

May 02, 2012

RNS Number : 5067C
BATM Advanced Communications Ld
02 May 2012

2 May 2012

BATM Advanced Communications Limited

CE certification for HCV (Hepatitis C) screening kit

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is pleased to announce that its wholly owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its HCV (Hepatitis C) Screening Kit.

The kit is a fourth generation Enzyme Immunoassay (Elisa) kit for the determination of antibodies to Hepatitis's C virus in human plasma or serum. Testing in external, independent labs has shown performance results of 100% for diagnostic sensitivity and 99.5% for diagnostic specificity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnoses and that laboratories are spared the significant and needless expense of repeat testing.

The kit enables two different method protocols, one especially developed for the Chinese market and a shorter version for the rest of the world.

This certification follows the Company's announcement of 23 March 2012 that it had received CE certification for its Detect 4 HIV Total Screening Kit.

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

Dr Zvi Marom, Chief Executive, of BATM commented:

"We're delighted to have received certification for the HCV screening kit which comes just after the clearance for our HIV kit. This is further evidence of the momentum that we are building within our medical division as we continue to add to our portfolio of products."

- Ends -

For further information:


BATM Advanced Communications +972 9866 2527

Ofer Bar-Ner, CFO

Newgate Threadneedle 020 7653 9850

Josh Royston / Graham Herring

finnCap 020 7220 0500

Marc Young / Brian Patient

Shore Capital 020 7408 4090

Pascal Keane

This information is provided by RNS
The company news service from the London Stock Exchange